Isotherm3G is a mesophilic DNA polymerase, perfectly suited for Isothermal amplifications. Isotherm3G has been mutated to have improved reverse transcription activity. It synthesizes DNA from both DNA and RNA templates with a high strand displacement activity allowing simplified one-enzyme RT-LAMP reactions.
Detail
Isotherm3G is a mesophilic DNA polymerase, perfectly suited for Isothermal amplifications. Isotherm3G has been mutated to have improved reverse transcription activity. It synthesizes DNA from both DNA and RNA templates with a high strand displacement activity allowing simplified one-enzyme RT-LAMP reactions.
Isotherm3G exhibits 5’ to 3’ polymerase activity but lacks any exonuclease activity. The product components have been optimized and are perfectly suited for loop-mediated isothermal amplification (LAMP) with optimal reaction temperature at 65°C.
Isotherm3G DNA Polymerase utilizes an aptamer-based warm-start feature to prevent false amplification at low temperatures. For more information, please contact us.
The product is available also in bulk quantities with custom fillings and can be produced customized for example in a lyo-ready formulation.
Other Products
cfDNA Purification Kit (Magnetic Beads)
Product Info
Document
Product Info
cfDNA Purification Kit (Magnetic Beads)
The cfDNA Purification Kit (Magnetic Beads) was developed for cell free DNA (cfDNA) enrichment by separating genomic DNA contamination from isolated cfDNA samples.
Many diagnostic technologies for detection of disease signals in cfDNA begin with isolation and purification of DNA from liquid biopsy that include urine, plasma, cerebrospinal fluid. The most widely explored biotechnology is assays used to detect cancer-derived plasma cfDNA. Silica-based magnetic bead cfDNA isolation kits can reliably extract total DNA from plasma, but typically yield a large variation in cfDNA that includes the presence of genomic DNA that often depends on tumor stage, tumor size, or healthy status individuals. Most of the commercial cfDNA isolation kits can’t specifically recover the cfDNA while leaving the high molecular weight genomic DNA behind. The presence of genomic DNA can lead to decreased sensitivity or inconsistent results in downstream applications such as next-generation sequencing (NGS), PCR, QPCR, and digital PCR etc.
Therefore, an additional purification step to enrich cfDNA before downstream methods helps to improve signal from fragments that originate from cancer cells. A proportion of cancer-derived cfDNA fragment signals are below 100 bp and are often not detectable except by qPCR or single-stranded DNA based library preparation for NGS (1, 2, 3). Furthermore only 1% of cancer-derived fragments are found above 400 bp (1, 2). Capture of size-selected fragments between 90-150 bp improved detection of cancer by 2-4 fold (4). Furthermore, TF-bound and protected cfDNA fragments are also being investigated for active cancer-specific signals down to 35-80 bp (5, 6).
This kit uses Dual Solid Phase Reversible Immobilization (SPRI) technology for cfDNA purification. Most Dual SPRI procedures do NOT recover fragments below 100 bp. The kit can be used for the enrichment of cfDNA isolated from liquid biopsies, plasma, serum, and urine. The kit separates cfDNA (50-500 bp) and genomic DNA, and recovers of 90% of the cfDNA without the high molecular weight genomic DNA with high efficiency. Fragments at 500 bp and above may also be retained. Both the 50-500 bp and >500 bp DNA fractions can be used for downstream applications such as single-stranded or double stranded NGS library prep, qPCR, ddPCR, and other methods.
Features
Separation of cfDNA and genomic DNA; Recovery of both types of DNA
Recovery of cfDNA (50-500 bp)
As short as 50 bp can be recovered
Recovery of high molecular weight genomic DNA
Removal of unwanted components and other impurities
Automation friendly
Examples of cfDNA purification. Both cfDNA and genomic DNA can be recovered separately.
The range of recovered small DNA fragments is from 50 to 500 bp. The input DNA are mixtures of sheared small DNA fragments and intact genomic DNA. The ratios of sheared DNA fragments versus genomic DNA are indicated.
Recovery rates of cfDNA and genomic DNA.
Document
Many diagnostic technologies for detection of disease signals in cfDNA begin with isolation and purification of DNA from liquid biopsy that include urine, plasma, cerebrospinal fluid. The most widely explored biotechnology is assays used to detect cancer-derived plasma cfDNA. Silica-based magnetic bead cfDNA isolation kits can reliably extract total DNA from plasma, but typically yield a large variation in cfDNA that includes the presence of genomic DNA that often depends on tumor stage, tumor size, or healthy status individuals. Most of the commercial cfDNA isolation kits can’t specifically recover the cfDNA while leaving the high molecular weight genomic DNA behind. The presence of genomic DNA can lead to decreased sensitivity or inconsistent results in downstream applications such as next-generation sequencing (NGS), PCR, QPCR, and digital PCR etc.
Lateral Flow Assay designed for the detection of IgG antibodies against PF4/polyanion-complexes in human citrated plasma or serum.
This product is only available in Germany!
Method/Platform
lateral flow, immunoassay
Range/Assay Sensivity
Test Principle
IgG antibodies are resposible for the heparin induced thrombocytopenia.
Immobilized anti-human IgG on the membrane of the test unit binds patients IgG-antibodies which are previously captured by the PF4/polyanion-complex which is detected by intensely colored gold nanoparticles.
The presence of PF4/polyanion-complex becomes visible at a colored test line. The surplus of gold particles continues to migrate through the membrane and is captured at the control line by specific antibodies.
Document
Lateral Flow Assay designed for the detection of IgG antibodies against PF4/polyanion-complexes in human citrated plasma or serum.
